吉西他滨和顺铂联合重组人血管内皮抑制素治疗晚期非小细胞肺癌临床观察

目的评价吉西他滨和顺铂联合重组人血管内皮抑制素（恩度）治疗晚期非小细胞肺癌的疗效和安全性。方法 38例病理确诊的晚期非小细胞肺癌患者给予吉西他滨和顺铂联合恩度治疗,吉西他滨1000mg/m2,第1,8天,顺铂75mg/m2,第2天,恩度注射液7.5mg/m2加入500ml生理盐水中,滴注时间3～4小时,第1～14日,每21天为一周期。结果 38例患者入组,部分缓解13例,疾病稳定17例,疾病进展8例,客观有效率为34.2%,疾病控制率为78.9%。本组中位无进展生存期为4.6个月,95%CI为2.600～6.600个月,中位生存期为13.5个月,95%CI为9.599～17.401个月,1年生存率42.1%。结论吉西他滨和顺铂联合恩度治疗晚期非小细胞肺癌,有较好的疗效和安全性,具有较好临床应用前景。

Clinical observation of gemcitabine plus cisplatin combined with rh-endostatin in advanced non-small cell lung cancer

Objective To evaluate the efficacy and toxicity of gemcitabine plus cisplatin combined with rh-endostatin （Endostar） as the chemotherapy in advanced non-small cell lung cancer （NSCLC）.Methods Thirty-eight pathologically-confirmed advanced NSCLC patients were received gemcitabine plus cisplatin combined with endostar as the chemotherapy.Gemcitabine were administered 1000 mg/m2 intravenously on day 1 and day 8,cisplatin 75mg/m2 on day 2 and endostar 7.5mg/m2 from day 1 to day 14 with 21 days as one cycle.Results：Thirty-eight patients were enrolled in this study,13 patients had a partial response （PR）,17 patients had a stable disease （SD）,8 patients had a progression disease （PD）,with an objective response rate of 34.2% and a disease control rate of 78.9%.The median progression free survival was 4.6 months （95% CI,2.6 to 6.6 months）,the median overall survival time was 13.5 months（95% CI,9.599 to 17.401 months） and 1 year survival was 42.1%.Conclusion It was effective and safety of gemcitabine plus cisplatin combined with endostar as the chemotherapy in advanced non small cell lung cancer.